Once upon a time: the curious case of a backward story of EGPA
Diego Bagnasco , Benedetta Bondi , Veronica Capuano , Frank Rikki Mauritz Canevari , Cesare De Tomaso , Sara Fedele , Vincenzo Milano , Marcello Mincarini , Michela Robbiano , Melania Bertolini , Fulvio Braido
Exploration of Asthma & Allergy ›› 2025, Vol. 3 ›› Issue (1) : 100975
A high percentage of patients with severe asthma also suffer from nasal polyposis, with dupilumab, an anti-IL-4R antibody both diseases can be treated due to its role in type 2 (T2) inflammation. When these conditions are associated with eosinophilic vasculitis, they may be classified as eosinophilic granulomatosis with polyangiitis (EGPA), which can be treated with mepolizumab. This case report presents an atypical form of EGPA, following an unusual course that began with the final signs and symptoms and then proceeded backward to the prodromal stages. Our patient, indeed, a 46-year-old woman, was asymptomatic throughout her youth, with the exception of nasal polyps. Later, at the age of 34, she developed late onset asthma, which became increasingly difficult to treat, until old and previously unacknowledged evidence of vasculitis was discovered, giving a twist to our patient’s medical history and, subsequently, to the therapeutic strategy adopted to treat her. This case report aims to highlight the importance of conducting a thorough anamnesis in patients suffering from both severe asthma and nasal polyposis, taking into account the high prevalence of EGPA in this category of patients, as well as its wide range of clinical manifestations, not to mention the various available therapeutic strategies, including mepolizumab.
EGPA / mepolizumab / severe asthma / vasculitis / dupilumab
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
/
| 〈 |
|
〉 |
PDF
(1815KB)
